Scholarlink

Background <p>Gastric cancer (GC) remains a global health burden. While international guidelines share consensus, variations exist in disputed issues. The <i>2025 Taiwan Consensus and Management Guidelines for Gastric Cancer</i> had just been released. We compared the key recommendations with established international guidelines.</p> Methods <p>A multidisciplinary taskforce addressed key questions and recommendations using modified Delphi method and evidence-based approaches. The comparative review aimed to elucidate similarities and differences among guidelines from Taiwan, Japan, South Korea, China, Europe, and the US.</p> Results <p>Guidelines converge on absolute endoscopic resection criteria for early GC but differ in extended indications and perioperative approaches for locally advanced disease. Heterogeneity exists in biomarker assessment protocols, cutoff thresholds, and companion diagnostics. For metastatic disease, consensus exists on anti-HER2, anti-VEGF, immunotherapy, and biomarker-driven strategies, though oligo-metastatic definitions and intraperitoneal chemotherapy indications remain controversial.</p> Conclusion <p>Optimal GC management requires integrating global evidence with regional contexts. The comparative review addresses heterogeneity among international guidelines, which helps harmonize management strategies as therapeutic standards evolve.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Chih-Chieh Yen,
  • I-Chen Wu,
  • Cheng-Chan Yu,
  • Ming-Huang Chen,
  • Nai-Jung Chiang,
  • Wen-Liang Fang,
  • Kuo-Hsing Chen,
  • Chieh-Chang Chen,
  • Tzu-Chan Hong,
  • Yen-Cheng Chen,
  • Ming-Wun Wong,
  • De-Chuan Chan,
  • I-Shu Chen,
  • Yen-Yang Chen,
  • Yueh-Wei Liu,
  • Jiann-Ming Wu,
  • Wen-Chi Chou,
  • Chan-Keng Yang,
  • Jun-Te Hsu,
  • Ta-Sen Yeh,
  • Li-Yuan Bai,
  • Yi-Fang Chang,
  • Yao-Yu Hsieh,
  • Cheng-Ming Peng,
  • Jaw-Yuan Wang,
  • Hui-Hua Hsiao,
  • Li-Tzong Chen,
  • Kun-Ming Rau,
  • Chia-Jui Yen,
  • Jen-Shi Chen,
  • Yan-Shen Shan

摘要

Background

Gastric cancer (GC) remains a global health burden. While international guidelines share consensus, variations exist in disputed issues. The 2025 Taiwan Consensus and Management Guidelines for Gastric Cancer had just been released. We compared the key recommendations with established international guidelines.

Methods

A multidisciplinary taskforce addressed key questions and recommendations using modified Delphi method and evidence-based approaches. The comparative review aimed to elucidate similarities and differences among guidelines from Taiwan, Japan, South Korea, China, Europe, and the US.

Results

Guidelines converge on absolute endoscopic resection criteria for early GC but differ in extended indications and perioperative approaches for locally advanced disease. Heterogeneity exists in biomarker assessment protocols, cutoff thresholds, and companion diagnostics. For metastatic disease, consensus exists on anti-HER2, anti-VEGF, immunotherapy, and biomarker-driven strategies, though oligo-metastatic definitions and intraperitoneal chemotherapy indications remain controversial.

Conclusion

Optimal GC management requires integrating global evidence with regional contexts. The comparative review addresses heterogeneity among international guidelines, which helps harmonize management strategies as therapeutic standards evolve.